PT699077E - Complexo imunogenico de hiv - Google Patents

Complexo imunogenico de hiv

Info

Publication number
PT699077E
PT699077E PT94917313T PT94917313T PT699077E PT 699077 E PT699077 E PT 699077E PT 94917313 T PT94917313 T PT 94917313T PT 94917313 T PT94917313 T PT 94917313T PT 699077 E PT699077 E PT 699077E
Authority
PT
Portugal
Prior art keywords
hiv
immunogenic complex
immunogenic
concanvalin
succinyl
Prior art date
Application number
PT94917313T
Other languages
English (en)
Inventor
Anthony Louis Dedico
Ranajit Pal
Mangalasseril G Sarngadharan
Original Assignee
Bio Merieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux Inc filed Critical Bio Merieux Inc
Publication of PT699077E publication Critical patent/PT699077E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/974Aids related test
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT94917313T 1993-05-07 1994-05-06 Complexo imunogenico de hiv PT699077E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6092693A 1993-05-07 1993-05-07

Publications (1)

Publication Number Publication Date
PT699077E true PT699077E (pt) 2002-04-29

Family

ID=22032603

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94917313T PT699077E (pt) 1993-05-07 1994-05-06 Complexo imunogenico de hiv

Country Status (10)

Country Link
US (6) US5843454A (pt)
EP (1) EP0699077B1 (pt)
JP (1) JPH08510246A (pt)
AT (1) ATE207760T1 (pt)
AU (1) AU680916B2 (pt)
DE (1) DE69428896T2 (pt)
DK (1) DK0699077T3 (pt)
ES (1) ES2166779T3 (pt)
PT (1) PT699077E (pt)
WO (1) WO1994026305A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
AU3960797A (en) * 1996-06-28 1998-01-21 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
DK1137786T3 (da) * 1999-10-08 2007-08-06 Univ Maryland Biotech Inst Viruscoatprotein/receptorkimærer og fremgangsmåder til brug heraf
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
FR2799974B1 (fr) * 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
US6503736B1 (en) * 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
BR0114094A (pt) 2000-09-22 2003-07-22 Univ Duke Imunógeno
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
AU2002243392A1 (en) * 2000-12-27 2002-07-30 Dana-Farber Cancer Institute, Inc. Immunogenic proteoliposomes, and uses thereof
AU2002335932B2 (en) * 2001-03-21 2007-11-01 Altarex Medical Corp. Therapeutic compositions that alter the immune response
AU2002337885B1 (en) * 2001-10-16 2003-04-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2003095492A1 (en) * 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7811580B2 (en) 2002-05-07 2010-10-12 Novartis Vaccines & Diagnostics, Inc. Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
CA2472438A1 (en) * 2002-06-28 2004-01-08 Fuso Pharmaceutical Industries, Ltd. Mannose binding protein for use in anti-hiv treatment
JP2005535636A (ja) 2002-06-28 2005-11-24 アメリカ合衆国 インターフェロンβおよびIL−2Rアンタゴニストを用いて自己免疫疾患を治療する方法
KR20050036960A (ko) * 2002-07-23 2005-04-20 듀크 유니버시티 IgG Fc/HIV-gp120/C3d 융합 단백질
JP4038679B2 (ja) * 2003-05-13 2008-01-30 住友電気工業株式会社 半導体レーザーバーの固定用治具
WO2005111621A2 (en) * 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
US8206720B2 (en) 2004-06-08 2012-06-26 Novartis Vaccines & Diagnostics, Inc Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes
WO2006026097A2 (en) * 2004-08-25 2006-03-09 Vijay Ramakrishnan Pegylation of antibodies against hiv
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
AU2005302416A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
ATE471947T1 (de) * 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
US8647818B2 (en) * 2005-02-18 2014-02-11 UAB Research Foundation, University of Alabama—Birmingham Molecular scaffolds for HIV-1 immunogens
CN101313216A (zh) * 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
US20100104580A1 (en) * 2008-09-03 2010-04-29 Philadelphia Health & Education Corporation D/B/A Altered Immunogenic Landscape in HIV-1 Envelope Proteins
US20110212119A1 (en) * 2008-10-31 2011-09-01 Proteonova, Inc. Methods for making hiv vaccines and related compositions
US8340810B2 (en) * 2008-10-31 2012-12-25 Spectra Logic Corp. Robotic storage library with queued move instructions and method of queuing such instructions
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103797029B (zh) * 2011-05-17 2016-08-17 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20150175678A1 (en) * 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2930587A1 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
US20160362478A1 (en) * 2014-02-10 2016-12-15 Navid Madani Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011299A1 (en) * 1989-03-03 1990-09-03 Franklin Volvovitz Aids therapy
EP0550516A1 (en) * 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus

Also Published As

Publication number Publication date
WO1994026305A1 (en) 1994-11-24
JPH08510246A (ja) 1996-10-29
US6328973B1 (en) 2001-12-11
EP0699077A1 (en) 1996-03-06
ES2166779T3 (es) 2002-05-01
DE69428896T2 (de) 2002-06-20
EP0699077B1 (en) 2001-10-31
US20030039663A1 (en) 2003-02-27
US5843454A (en) 1998-12-01
AU680916B2 (en) 1997-08-14
DE69428896D1 (de) 2001-12-06
DK0699077T3 (da) 2002-01-21
US6465172B1 (en) 2002-10-15
ATE207760T1 (de) 2001-11-15
US6030772A (en) 2000-02-29
AU6907394A (en) 1994-12-12
US5518723A (en) 1996-05-21

Similar Documents

Publication Publication Date Title
PT699077E (pt) Complexo imunogenico de hiv
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
SG77551A1 (en) Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
AU606951B2 (en) Synthetic peptide antigen for the detection of hiv-2 infection
AU4985496A (en) Administration of a cyclosporine-specific monoclonal antibody that cross-reacts with hiv-1 p24 gag to treat hiv infection
AU5510794A (en) Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) gp120 and methods of use
AU563356B2 (en) Conjugate of enzyme and antibody
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
DE68906366D1 (en) Cd4-polypeptidderivate.
DE69029937D1 (de) FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
ES2182833T3 (es) Agentes antitromboticos multimeros polivalentes.
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
GR1002294B (el) Συνδυασμενο εμβολιο για streptococcus ομαδας β.
DE69435142D1 (de) Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen
CA2160922A1 (en) Hiv immunogenic complexes
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
AU5695294A (en) Monoclonal antibodies against a carbohydrate-dependent epitope related to the V2 region of HIV-1 GP120
EP0345559A3 (en) Hiv-2 variants
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
DE68926454T2 (de) Gegen hiv 1 gp48 spezifische antikörper
BG98538A (en) Means for anti-hiv therapy
RU95122192A (ru) Сем-к - штамм перевиваемых клеток человека, устойчивый к вич-инфекции